Seminars in arthritis and rheumatism最新文献

{"title":"Prognostic significance and rationality of regular non-invasive imaging follow-up in Takayasu arteritis: A large multicenter cohort study","authors":"Fatih Yıldırım ,&nbsp;Fatih Tastekin ,&nbsp;Safiye Bakkal ,&nbsp;Muhammet Emin Kutu ,&nbsp;Tuğba Ocak ,&nbsp;Senar San ,&nbsp;Aysegul Avcu ,&nbsp;Hasan Kocaayan ,&nbsp;Sema Işık ,&nbsp;Burcu Ceren Uludogan ,&nbsp;Gökçe Kenar Artın ,&nbsp;Yavuz Pehlivan ,&nbsp;Ediz Dalkilic ,&nbsp;Nazife Sule Yasar Bilge ,&nbsp;Fatma Alibaz-Oner ,&nbsp;Ahmet Omma ,&nbsp;Ayten Yazici ,&nbsp;Ayse Cefle ,&nbsp;Servet Akar ,&nbsp;Cemal Bes ,&nbsp;Nilüfer Alpay Kanıtez","doi":"10.1016/j.semarthrit.2025.152813","DOIUrl":"10.1016/j.semarthrit.2025.152813","url":null,"abstract":"<div><h3>Objectives</h3><div>To investigate the prognostic significance of regular imaging follow-up in Takayasu arteritis (TAK) and assess its rationality.</div></div><div><h3>Methods</h3><div>This was a retrospective multicenter cohort study. A total of 204 adult patients with TAK from 11 tertiary centers, and 580 imaging studies of these patients were included to encompass all concurrent clinical and laboratory findings.</div></div><div><h3>Results</h3><div>The median follow-up time was 72 (36-96) months. Radiological activity and/or progression was observed in 116 (20 %) of the 580 imaging. A total of 418 (72 %) of the 580 imaging were performed while the physician’s global assessment (PGA) was inactive. Radiological activity and/or progression was observed in only 18 (4 %) of the PGA inactive imaging. Younger age [OR 0.980; 95 % CI: 0.961-0.999, <em>P</em> = 0.041] and active PGA [OR 31.766; 95 % CI: 17.961-56.219, <em>P</em> &lt; 0.001] were predictors of radiological activity and/or progression. There was no difference in terms of disease outcomes (MACE, VDI score, and mortality) between patients who underwent regular imaging follow-up regardless of clinical activity once a year or more and others.</div></div><div><h3>Conclusion</h3><div>In the absence of clinical activity, the rate of radiological activity and/or progression is very low in patients with TAK during routine follow-up. It seems more reasonable to develop a personalised imaging follow-up plan that takes clinical activity findings into account rather than regular imaging follow-up.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152813"},"PeriodicalIF":4.4,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144892050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between pain and depression and anxiety in people with inflammatory arthritis: A systematic review","authors":"Natasha Cox ,&nbsp;Ashley Hawarden ,&nbsp;Chelsea Kettle ,&nbsp;Ram Bajpai ,&nbsp;Saeed Farooq ,&nbsp;Helen Twohig ,&nbsp;Sara Muller ,&nbsp;Ian C Scott","doi":"10.1016/j.semarthrit.2025.152808","DOIUrl":"10.1016/j.semarthrit.2025.152808","url":null,"abstract":"<div><h3>Objective</h3><div>This PROSPERO-registered (CRD42023411823) systematic review synthesised literature on the associations between pain and depression/anxiety in inflammatory arthritis, including the direction of effect, relationship mediators, and treatment impacts.</div></div><div><h3>Methods</h3><div>Protocolised-database searches were conducted to May-2023 and studies assessing the associations between pain and depression/anxiety and/or impacts of depression/anxiety treatment on pain in people with rheumatoid arthritis/spondyloarthritis identified. Studies with mixed-populations, non-translatable non-English studies, case-reports/series/reviews/editorials, and abstracts/letters with insufficient-data were excluded. Vote-counting/meta-analysis synthesised single-time-point associations. Narrative synthesis summarised longitudinal associations/mediators/treatment effects. JBI critical-appraisal tools and the Grading of Recommendations, Assessment, Development and Evaluations approach evaluated risk-of-bias and strength-of-evidence.</div></div><div><h3>Results</h3><div>Seventy-nine studies were included. A bidirectional relationship between pain and depression was observed. At single-time-points, pain was higher in those with depression (standardised mean difference [SMD]=0.69 [95%CI 0.54,0.84]; representing a moderate effect as per Cohen’s criteria); linear regressions demonstrated moderate associations between pain (outcome) and depression (explanatory-variable) (SMD=0.65 [0.31,0.99]) and small associations between depression (outcome) and pain (explanatory-variable) (SMD=0.24 [0.03,0.45]). Longitudinal studies indicated greater pain with worse depression. Findings were mixed for anxiety. Linear regressions showed minimal associations between pain (outcome) and anxiety (explanatory-variable) (SMD=0.03 [0.001,0.05]) and moderate between anxiety (outcome) and pain (explanatory-variable) (SMD=0.55 [0.20,0.91]). Two longitudinal studies considered mediators (one suggesting “passive coping” in depression). Trials indicated anti-depressants reduced pain in people with comorbid-depression. Thirty-five percent of studies were at high, 34% moderate, and 30% low risk-of-bias; evidence was very low/low-quality.</div></div><div><h3>Conclusion</h3><div>A modest bidirectional association exists between pain and depression in inflammatory arthritis (based on very low-quality evidence), supporting biopsychosocial pain management.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152808"},"PeriodicalIF":4.4,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144925750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fibrosis mechanisms and updates in potential therapeutic targets in systemic sclerosis","authors":"Xue Han ,&nbsp;Xiuyuan Wang ,&nbsp;Junxia Huang,&nbsp;Ji Yang","doi":"10.1016/j.semarthrit.2025.152811","DOIUrl":"10.1016/j.semarthrit.2025.152811","url":null,"abstract":"<div><div>Systemic sclerosis (SSc) is a rare, multisystem autoimmune connective tissue disease characterized by microvascular dysfunction, inflammation, and progressive fibrosis. The pathogenesis of SSc is regulated by both epigenetic and genetic factors. Although the pathogenesis is being explored, treatment options, especially for fibrosis, remain limited. Recent clinical trials have made significant progress in targeting key pathways in fibrosis. This review discusses emerging therapeutic strategies, focusing on targets such as TGF-β signaling, oncostatin M/OSM receptor β axis, lysophosphatidic acid, nuclear receptor superfamily, endocannabinoid system, soluble guanylate cyclase, and mesenchymal stem cells, and highlights the potential of these targets to improve patient outcomes in combination with relevant clinical trials.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152811"},"PeriodicalIF":4.4,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144902268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Further expanding the clinical spectrum of giant cell arteritis: Non-classical organ involvement and uncommon complications","authors":"Javier Narváez,&nbsp;Paola Vidal-Montal,&nbsp;Pol Maymó-Paituvi,&nbsp;Judith Palacios-Olid,&nbsp;Martí Aguilar-Coll,&nbsp;Montserrat Roig-Kim,&nbsp;Laia de Daniel-Bisbe,&nbsp;Joan Miquel Nolla","doi":"10.1016/j.semarthrit.2025.152817","DOIUrl":"10.1016/j.semarthrit.2025.152817","url":null,"abstract":"<div><h3>Objective</h3><div>The increasing use of imaging techniques, particularly 18F-FDG PET-CT, together with autopsy findings, has significantly expanded our understanding of the clinical spectrum of giant cell arteritis (GCA). This study aimed to assess the frequency and spectrum of non-classical manifestations and other infrequent complications of the disease</div></div><div><h3>Methods</h3><div>This retrospective study analyzed a consecutive cohort of 174 patients with proven GCA diagnosed between 2005 and 2024.</div></div><div><h3>Results</h3><div>Among 174 GCA patients, 52 (29.9%) presented with one or more non-classical organ manifestations, including cardiac involvement in 7.5% (ischaemic heart disease or pericarditis), primary respiratory disease in 13.8% (pleural disease, sore throat, persistent dry cough, interstitial lung disease, and pulmonary inflammatory nodules), neurological complications beyond strokes in 2.3% (peripheral neuropathy, epilepsy, and spinal cord infarction), gastrointestinal involvement in 1.1%, and increased 18F-FDG uptake in salivary glands in 5.7%. Beyond these manifestations, PET-CT at diagnosis revealed uncommon medium-to-large vessel involvement, including renal artery vasculitis in 2.9% (without renal insufficiency or urinary abnormalities) and asymptomatic splanchnic involvement (coeliac trunk or superior mesenteric artery) in 4.6%. Other infrequent manifestations included secondary amyloidosis in 1.1%, necrosis or involvement of the scalp, tongue, or lips in 2.3%, carotidynia in 5.2%, overt audiovestibular involvement (including sensorineural hearing loss or vestibular dysfunction) in 3.4%, musculoskeletal symptoms beyond PMR in 10.3% (peripheral arthritis and remitting distal extremity swelling with pitting oedema), diffuse increase in bone marrow 18F-FDG uptake in 15.5%, and polyautoimmunity in 10.3%.</div></div><div><h3>Conclusion</h3><div>Beyond the classical cranial and extracranial patterns, which often coexist, a significant proportion of GCA patients may present with atypical or non-classical complications, sometimes as the initial manifestation. These should be considered during evaluation and follow-up, as early recognition and treatment are key to reducing morbidity and mortality.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152817"},"PeriodicalIF":4.4,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144841787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual positivity for Anti-Ro52 and Anti-Ro60 antibodies is linked to greater organ involvement and disease progression in systemic sclerosis","authors":"Hanlin Yin ,&nbsp;Wanyi Lin ,&nbsp;Chenhan Jia ,&nbsp;Chaoyu Gu ,&nbsp;Zhangyi Zhao ,&nbsp;Fenglin Wu ,&nbsp;Qianqian Li ,&nbsp;Yan Ma ,&nbsp;Xinyu Li ,&nbsp;Zhe Ding ,&nbsp;Xuesong Liu ,&nbsp;Xinyi Liu ,&nbsp;Le Zhang ,&nbsp;Liangjing Lu","doi":"10.1016/j.semarthrit.2025.152810","DOIUrl":"10.1016/j.semarthrit.2025.152810","url":null,"abstract":"<div><h3>Objectives</h3><div>To investigate the distinct and combined effects of anti-Ro52/TRIM21 and anti-Ro60/SSA antibodies on the clinical features and prognosis of patients with systemic sclerosis (SSc).</div></div><div><h3>Methods</h3><div>A single-center observational study was conducted using data from the Renji Scleroderma Longitudinal Cohort (Renji-SLOC), including 379 SSc patients with at least 1 year of follow-up. The patients were categorized into four groups based on serological status: double-negative (Ro52⁻/Ro60⁻), isolated anti-Ro52/TRIM21 positive (Ro52⁺), isolated anti-Ro60/SSA positive (Ro60⁺), double-positive (Ro52⁺/Ro60⁺). Clinical features and disease progression were analyzed using multivariable logistic regression and survival analysis.</div></div><div><h3>Results</h3><div>Among 379 patients, 12.7% (n=48) were double-positive. Notably, 43.6% of Ro52-positive patients were also Ro60-positive, and 62.3% of Ro60-positive patients were Ro52-positive, indicating significant co-occurrence. Double-positive patients exhibited significantly higher rates of ILD (79.2%), PAH (25.0%), digital ulcers (41.7%), and gastrointestinal symptoms (79.2%). Multivariable analysis confirmed that double positivity independently increased risks of ILD (adjusted OR=2.27, 95% CI=1.02-5.14), PAH (adjusted OR=2.24, 95% CI=1.03-4.84), digital ulcers (adjusted OR=3.12, 95% CI=1.57-6.20), and gastrointestinal involvement (adjusted OR=2.28, 95% CI=1.08-4.81). Survival analysis demonstrated significantly worse progression-free survival in double-positive patients (adjusted HR=1.90, 95% CI=1.24-2.90 for overall progression; adjusted HR=2.20, 95% CI=1.36-3.57 for ILD progression, both p&lt;0.05).</div></div><div><h3>Conclusion</h3><div>Dual positivity for anti-Ro52 and anti-Ro60 antibodies identifies a distinct SSc subgroup with severe organ involvement and accelerated disease progression, particularly ILD. These findings highlight the prognostic value of combined antibody testing and underscore the need for vigilant monitoring in double-positive patients.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152810"},"PeriodicalIF":4.4,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144858196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of sit-to-stand, timed up-and-go, and six-minute walk tests in home and office settings in patients with idiopathic inflammatory myopathy","authors":"Didem Saygin ,&nbsp;Anjana Chandrasekhara Pillai ,&nbsp;Amanda Kocoloski Wakeley ,&nbsp;Chester V. Oddis ,&nbsp;Siamak Moghadam-Kia ,&nbsp;Rohit Aggarwal","doi":"10.1016/j.semarthrit.2025.152809","DOIUrl":"10.1016/j.semarthrit.2025.152809","url":null,"abstract":"<div><h3>Background</h3><div>Patients with idiopathic inflammatory myopathies (IIM) frequently experience limitations in their physical function. Sit-to-stand (STS), timed-up-and-go (TUG), and six-minute walk distance (6MWD) are task-oriented functional tests that can provide objective information about physical function. In this study, we assess their measurement properties in office and home settings.</div></div><div><h3>Methods</h3><div>Adults with IIM were enrolled in a prospective study. Patients performed the functional tests (STS, TUG, 6MWD) at 0-, 3- and 6-months, and self-performed these tests at home within 14-days of the visit. Several patient centered outcome measures (PCOMs) were obtained: fatigue (visual analog scale [VAS]), pain (VAS), quality of life (SF-36), physical function (PROMIS, SF36), and physical activity (Actigraphy). Spearman correlation, effect size, standardized response mean, and regression models were used to assess cross-sectional and longitudinal association between functional tests and other measures.</div></div><div><h3>Results</h3><div>Fifty patients (mean age 51.6, 60% female) were enrolled. Twenty-four, 23, and 20 completed at-home STS, TUG, and 6MWD, respectively. STS and TUG showed strong test-retest reliability at both home and office settings. 6MWD was significantly higher at office setting, whereas TUG/STS was comparable between home and office. All three functional tests significantly discriminated between active vs inactive disease and had significant cross sectional and longitudinal association with PCOMs of physical function, quality of life, and physical activity.</div></div><div><h3>Conclusion</h3><div>STS, TUG and 6MWD have good test-retest reliability, validity and responsiveness. 6MWD has poor reliability when self-performed at home, while STS/TUG perform similarly in the office and home settings.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152809"},"PeriodicalIF":4.4,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144863843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Traditional laboratory parameters and IFNγ-related biomarkers in the diagnosis and management of MAS","authors":"Arianna De Matteis ,&nbsp;Manuela Pardeo ,&nbsp;Ivan Caiello ,&nbsp;Valentina Matteo ,&nbsp;Denise Pires Marafon ,&nbsp;Emanuela Sacco ,&nbsp;Francesca Minoia ,&nbsp;Elena Loricchio ,&nbsp;Francesco Licciardi ,&nbsp;Angela Miniaci ,&nbsp;Ilaria Maccora ,&nbsp;Clotilde Alizzi ,&nbsp;Giusi Prencipe ,&nbsp;Fabrizio De Benedetti ,&nbsp;Claudia Bracaglia","doi":"10.1016/j.semarthrit.2025.152812","DOIUrl":"10.1016/j.semarthrit.2025.152812","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate diagnostic and prognostic significance of traditional laboratory parameters of hyperinflammation and of the IFNγ-related biomarkers interleukin-18 (IL-18), CXCL9 and neopterin in macrophage activation syndrome (MAS) secondary to Still’s disease (SD).</div></div><div><h3>Methods</h3><div>Forty-one patients with MAS and 24 patients with active pediatric SD from six Italian centers were enrolled. Samples were obtained at baseline (at initiation or within 48 hours of initiation of specific treatments) for MAS or active SD and at T1 (5-15 days from baseline) only from MAS. CXCL9, IL-18 and neopterin were measured by ELISA. The MAS clinical severity score (MCSS) was developed to define MAS severity (mild: score 0-4; severe: score 5-8).</div></div><div><h3>Results</h3><div>In addition to the parameters included in the 2016 MAS criteria, lymphopenia and increased LDH reliably discriminated MAS from active SD. Levels of CXCL9, IL-18 and neopterin effectively discriminated MAS from active SD. Higher levels of the three IFNγ-related biomarkers at baseline were associated with a severe course MAS (MCSS&gt;4). Combining levels at baseline of CXCL9 with those of ferritin, platelet count, fibrinogen and LDH, led to a prognostic score with sensitivity of 100 % and specificity of 74 % for severe MAS. Contingency analysis showed that CXCL9 &gt;830 pg/ml and IL-18 &gt;83,000 pg/ml at T1 had a significant risk of failing to achieve MAS remission in ≤2 months (odds ratio 9.3 and 5.4, respectively).</div></div><div><h3>Conclusions</h3><div>These findings highlight the potential role of CXCL9 measurement in supporting the diagnosis and guiding the therapeutic management of patients with MAS in clinical practice.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152812"},"PeriodicalIF":4.4,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144879201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of oral semaglutide on serum urate levels in people with type 2 diabetes: A retrospective real-world analysis (URISEMA study)","authors":"Oscar Moreno-Pérez ,&nbsp;Antonio Tejera-Muñoz ,&nbsp;Rubén Carreño-Valdivia ,&nbsp;María Rodríguez-Bedoya ,&nbsp;Cristina Guillén-Morote ,&nbsp;Ada Roldán-Sánchez ,&nbsp;Mariano Andrés","doi":"10.1016/j.semarthrit.2025.152807","DOIUrl":"10.1016/j.semarthrit.2025.152807","url":null,"abstract":"<div><h3>Background</h3><div>Evidence on the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on serum urate (SU) levels in people with type 2 diabetes (PWT2D) is limited. This study investigates the effect of oral semaglutide on SU levels.</div></div><div><h3>Methods</h3><div>Retrospective, observational study including PWT2D who were prescribed oral semaglutide. The primary endpoint was achieving SU levels below 6 mg/dL at 12 months of follow-up (FU). Secondly, we assessed baseline factors associated with achieving SU levels of &lt;6 mg/dL and average reductions in SU levels.</div></div><div><h3>Results</h3><div>The study included 236 patients (median age 64 years, BMI 33.8 kg/m², HbA1c 7.6 %, 40.7 % women, 52.3 % on SGLT2 inhibitors). Baseline SU was 5.2 mg/dL, 66.1 % had SU levels &lt;6 mg/dL, and 23.7 % had hyperuricemia. Under oral semaglutide, 70.7 % and 76 % showed SU &lt;6 mg/dL at 6 and 12 months, respectively. After multivariate adjustment, only SU ≥7 mg/dL (OR 4.54, 95 %CI 1.08–19.25) and switching from a DPP-4 inhibitor (OR 6.53, 95 %CI 1.57–27.32) were associated with achieving the SU target. SU decreased by 0.1 mg/dL after 6 months (<em>p</em> = 0.52) and by 0.2 mg/dL (<em>p</em> = 0.01) at 12 months FU. Greater reductions were observed in those with baseline SU &gt;6 mg/dL (0.6 mg/dL and 0.8 mg/dl, respectively; all <em>p</em> &lt; 0.001). Changes in SU levels were independent of improved metabolic control, weight loss, or baseline use of GLP-1 RAs or SGLT2 inhibitors.</div></div><div><h3>Conclusion</h3><div>Oral semaglutide in real-world settings showed a modest reduction in SU levels in PWT2D, particularly linked to baseline hyperuricemia (with notable reduction figures) and switching from DPP-4 inhibitors.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152807"},"PeriodicalIF":4.4,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144831275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of new onset of immune-mediated diseases after SARS-CoV-2 infection: A systematic review and meta-analysis","authors":"Ana M. Gil ,&nbsp;Julián Barahona-Correa ,&nbsp;Jorge B. Flórez ,&nbsp;Daniel G. Fernández-Ávila ,&nbsp;Zulma M. Cucunubá","doi":"10.1016/j.semarthrit.2025.152805","DOIUrl":"10.1016/j.semarthrit.2025.152805","url":null,"abstract":"<div><h3>Objectives</h3><div>The association between SARS-CoV-2 infection and new onset of immune-mediated diseases is of interest given the conflicting evidence. This study aims to gather evidence and estimate the risk of immune-mediated diseases following SARS-CoV-2 infection.</div></div><div><h3>Methods</h3><div>Analytical observational studies reporting immune-mediated diseases after confirmed SARS-CoV-2 infection, compared to individuals without infection history, were included. Thirty-nine immune-mediated diseases were defined as outcomes of interest. Studies including diagnosis within the first 30 days post-infection were excluded. PubMed, EMBASE, CINAHL, Web of Science, and Europe PMC were consulted. Relative risks were pooled using a random-effects model and the Mantel-Haenszel method.</div></div><div><h3>Results</h3><div>Eight studies met the eligibility criteria. Meta-analyses were conducted for 13 outcomes of interest from six studies. The SARS-CoV-2 exposed group exhibited significantly higher risks for 11 conditions compared to non-exposed group: Behçet's disease, spondyloarthritis, systemic sclerosis, systemic lupus erythematosus, polymyalgia rheumatica, psoriasis, rheumatoid arthritis, Sjögren's syndrome, type 1 diabetes (in adults), vasculitis, and inflammatory bowel disease. The range of the associations varied between 2.31 (95 % CI: 1.87–2.85) for systemic sclerosis to 3.71 (95 % CI: 1.18–11.72) for Behçet's disease. Guillain-Barré syndrome and type 1 diabetes (in the paediatric population) showed no evidence of association with SARS-CoV-2 infection.</div></div><div><h3>Conclusion</h3><div>Our results support a higher risk of developing at least 11 immune-mediated diseases evaluated. As autoimmunity is a hallmark of post-COVID-19 syndrome, an increase in these diseases may be expected in the future. Healthcare professionals and stakeholders should prioritize research and public health surveillance based on these findings.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152805"},"PeriodicalIF":4.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144831350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CNO/SAPHO: is it time for new serological biomarkers?","authors":"Caterina Matucci-Cerinic ,&nbsp;Roberta Caorsi ,&nbsp;Gianmaria Viglizzo ,&nbsp;Marco Gattorno","doi":"10.1016/j.semarthrit.2025.152802","DOIUrl":"10.1016/j.semarthrit.2025.152802","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152802"},"PeriodicalIF":4.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144858197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}